Publications by authors named "Josue O Jaramillo-Polanco"
Background: Monosodium glutamate (MSG) has been identified as a trigger of abdominal pain in irritable bowel syndrome (IBS), but the mechanism is unknown. This study examined whether MSG causes visceral hypersensitivity using a water-avoidance stress (WAS) mouse model of visceral pain.
Methods: Mice were divided into four groups receiving treatment for 6 days: WAS + MSG gavage, WAS + saline gavage, sham-WAS + MSG gavage, and sham-WAS + saline gavage.
Article Synopsis
- - The study investigates how dietary changes, specifically reducing fermentable carbohydrates, can alleviate pain in patients with irritable bowel syndrome (IBS) and how it relates to gut microbiota and neuroactive substances.
- - Participants followed a diet that alternated between low and high fermentable carbohydrates, while their symptoms, stool samples, and nerve reactions were monitored to assess the impact of these diets.
- - Results showed that a low-fermentable diet significantly reduced IBS symptoms and altered the activity of nerve cells, indicating that dietary changes may influence pain signaling through the gut's biochemicals.
Objective: The effectiveness of µ-opioid receptor (MOPr) agonists for treatment of visceral pain is compromised by constipation, respiratory depression, sedation and addiction. We investigated whether a fentanyl analogue, (±)-N-(3-fluoro-1-phenethylpiperidine-4-yl)-N-phenyl propionamide (NFEPP), which preferentially activates MOPr in acidified diseased tissues, would inhibit pain in a preclinical model of inflammatory bowel disease (IBD) without side effects in healthy tissues.
Design: Antinociceptive actions of NFEPP and fentanyl were compared in control mice and mice with dextran sodium sulfate colitis by measuring visceromotor responses to colorectal distension.
Background: A low fermentable carbohydrate (FODMAP) diet is used in quiescent inflammatory bowel disease when irritable bowel syndrome-like symptoms occur. There is concern that the diet could exacerbate inflammation by modifying microbiota and short-chain fatty acid (SCFA) production. We examined the effect of altering dietary FODMAP content on inflammation in preclinical inflammatory models.
View Article and Find Full Text PDF